Récepteurs solubles de lymphotoxine-bèta et anticorps contre le récepteur de lymphotoxine et contre le ligand de lymphotoxine comme agents thérapeutiques pour le traitement des maladies immunologiques
This disclosure relates to compositions and methods comprising "lymphotoxin-β receptor blocking agents" which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This disclosure relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This disclosure also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
